Table 2.
Elimination half-life of various biologic therapies
| Elimination half-life (t1/2) | Frequency of administration indicated in the SPC | |
|---|---|---|
| Golimumab | 12 (s.d. 3) days | Monthly |
| Etanercept | 70 h, range (7–300 h) | 50 mg: weekly 25 mg: 72 h |
| Adalimumab | 2 weeks | Every 2 weeks |
| Anakinra | 4–6 h | Daily |
| Certolizumab | 2 weeks | Every 2 weeks |
| Infliximab | 8–10 days | Every 8 weeks |
| Tocilizumab | 10–16 days depending on dose and age | Every 4 weeks |
| Abatacept | 8–25 days | i.v.: every 4 weeks s.c.: weekly |
These data were obtained from the SPC of each medicine available from the EMA. SPC: summary of product characteristics; EMA: European Medicines Agency.